Droplet Biosciences, Inc, a biotechnology start-up based in Cambridge, MA, has raised $8 million in seed funding from The Engine. The company is revolutionizing cancer care by leveraging the powerful insights gained from the lymphatic fluid through the development of the first lymph liquid biopsy.

Droplet's technology allows for the isolation and analysis of rare cells and molecules in the lymphatic system, which can provide critical information about cancer progression and response to treatment. This breakthrough approach can improve cancer diagnosis, monitoring, and treatment, improving patient outcomes. The company's innovative platform has already shown promise in early studies, with the potential to detect cancer earlier and more accurately than current methods.

With the new funding, Droplet plans to develop further and commercialize its technology, focusing on expanding its capabilities and bringing its products to market.

Droplet Biosciences, Inc is poised to make a significant impact in the field of cancer diagnostics and treatment. The recent seed funding from The Engine provides the resources necessary to complete that impact a reality. Visit our latest funding rounds for more information: https://founderlodge.com/round/Droplet-Biosciences-Inc-raises-8000000-Seed-2023-03-17-Theresa-Tribble-MTEwMzM.